Is REPL Worth Buying in 2026?

Replimune Group, Inc.

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-06-07

Here’s whether Replimune Group, Inc. (REPL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.45% over 10 days); 3-month momentum positive (+9.7%); rising volume confirms the move (1.25x 30d avg). Concerns: RSI 77 — overbought, elevated pullback risk. Currently 28.5% off its 52-week high. Score: +5/7.

Ready to act on this? 📈 Trade on Webull

REPL is in a confirmed uptrend, trading above both its 50-day ($4.96) and 200-day ($6.89) moving averages. With an RSI of 77.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -2.9% compares to +24.4% for SPY (trailed the market by 27.2%). The current 28.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $9,713 today
vs. S&P 500 (SPY) — same period trailed market by 27.2%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($6.89)
Above 50-day MA ($4.96)
!RSI(14) neutral zone (30–70) — currently 77.1
Positive return (-2.9%)
!Within 10% of period high (−28.5%)
Period Range $9.47
$1.50 $13.24
RSI (14) 77.1
0 · OversoldOverbought · 100

Key Metrics

Price$9.47
Period Return-2.9%
Period High$13.24
Period Low$1.50
Drawdown−28.5%
MA-50$4.96
MA-200$6.89
RSI (14)77.1
Avg Volume (30d)8.0M
vs. SPYtrailed by 27.2%
Return Rank#736 of 1245

Trade REPL

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers